Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3560607 A
Publication typeGrant
Publication dateFeb 2, 1971
Filing dateJul 5, 1968
Priority dateNov 30, 1962
Also published asDE1208036B
Publication numberUS 3560607 A, US 3560607A, US-A-3560607, US3560607 A, US3560607A
InventorsPhilip Saxton Hartley
Original AssigneeFisons Pharmaceuticals Ltd
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Aerosol formulations of finely divided solid medicaments with anionic surface-active agents
US 3560607 A
Images(4)
Previous page
Next page
Description  (OCR text may contain errors)

United States Patent M AEROSOL FORMULATIONS OF FINELY DIVIDED SOLID MEDICAMENTS WITH ANIONIC SUR- FACE-ACTIVE AGENTS Philip Saxtou Hartley, Springfield, Kegworth, England,

assignor to Fisons Pharmaceuticals Limited, Loughborough, Leicestershire, England No Drawing. Continuation-impart of application Ser. No. 324,222, Nov. 18, 1963. This application July 5, 1968, Ser. No. 742,521

Int. Cl. A61c 27/00 US. Cl. 424-46 5 Claims ABSTRACT OF THE DISCLOSURE Aerosol formulations are provided comprising a finely divided solid medicament, a propellant, and an anionic surface-active agent selected from the group consisting of alkali metal, ammonium and amine salts of dialkyl sulphosuccinic acids wherein the alkyl groups contain from 4 to 12 carbon atoms, and alkali metal, ammonium and amine salts of alkylbenzene sulphonic acids wherein the alkyl groups contain from 8 to 14 carbon acids.

This application is a continuation-in-part application of application Ser. No. 324,222, filed Nov. 18, 1963, now abandoned.

The present invention relates to powdered medicament formulations for use in pressurized dispensing containers (hereinafter termed aerosol formulations and containers).

Aerosol formulations find wide use inter alia, as a means of applying a medicament to a patient, for ex ample by way of inhalation. In general, such formulations comprise the material to be dispensed in admixture with a propellant therefor, which propellant is usually a liquefied material which is gaseous at ambient t mperatures. Such formulations are held in a container provided with a valved outlet, which may or may not be adapted to release uniform doses of material, the volatilisation of the liquefied material generating a pressure within the container. Upon operation of the valved outlet, the contents of the container are discharged as a fine spray. The general construction of the container and valved outlet are well known in the aerosol art, as is the use of a wide variety of liquefied materials, notably halogenated hydrocarbons, as propellants.

Where the material to be dispensed is not soluble in the propellant material to be used, as may be the case with a finely divided solid medicament, it is necessary to have present in the aerosol formulation a suspending agent to ensure that the solid material is satisfactorily suspended. Hitherto it has been considered necessary to use surface-active agents which were non-ionic in nature to achieve satisfactory suspension of the solid medicament and other materials, since ionic surface-active agents were considered to have too low a solubility in the liquefied propellant medium to be effective. The non-ionic surfaceactive agents which are in current commercial use include the ethylene oxide condensates of phenols and esters or partial esters of fatty acids. Typical of such compounds are those materials sold under the trademarks Span and Arlacel. Furthermore, it has also been considered necessary to use comparatively large amounts of these materials to achieve satisfactory results and the use of 100% or more by weight of surface-active agent based on the weight of solid material to be suspended is commonplace in commercial formulations. I

It will be appreciated that in a pharmaceutical composition, especially one which is to be ingested, e.g. inhaled, by the user, it is highly desirable that the composition Patented Feb. 2, 1971 contain the minimum of materials, other than those which are clearly inactive diluents, which could in any way affect the user detrimentally. However reduction in the amounts of non-ionic surface-active agents in formulations of the type described above has resulted in formulations in which the solid materials were not satisfactorily suspended.

Surprisingly, I have found that certain anionic surfaceactive agents may be used as suspending agents in powder aerosol formulations, and that these anionic surface-active agents may be used at far lower concentration than has been hitherto considered necessary for the non-ionic surface-active agents in present use. The use of the anionic surface-active agents of the invention has the advantages that the amount of material in the formulation other than the pharmaceutical may be reduced to a level below that hitherto attained; that certain desirable propellants of low toxicity which are incompatible with non-ionic surface-active agents may be used; and that a material, which is water-soluble and hence does not inhibit the assimilation of the powdered medicament upon presentation to the mucous membranes, is used whereas non-ionic surface-active agents are generally water-insoluble and cover the powder particles as a comparatively thick waterinsoluble coating. A further surprising feature of the use of the anionic surface-active agents of the invention is that in many cases the amount of surface-active agent required to suspend the solid material does not depend directly on the amount of solid material present. Thus, it is possible to obtain adequate suspension of powdered medicament present as up to 5% by weight of the total formulation with 0.004% by weight of the total formulation of sodium dioctyl sulphosuccinate, i.e. using amounts of surface-active agent to medicament ranging from say 0.4% by weight at 1% medicament to 0.08% by weight at 5% medicament. This is to be contrasted with the nonionic surface-active agents which require to be used in much larger amounts and in amounts more directly proportional to the amount of solid present.

The fact that the anionic surface-active agents of the invention should be effective at all in powder aerosol formulations is wholly unexpected since other commonly used anionic surface-active agents have been found to be totally ineffective, in that they were not sufficiently soluble in the propellant medium to provide solutions of equivalent concentration to those used with non-ionic surface-active agents and at the very low concentration of compound in liquefied propellant medium, which could be achieved before the compounds themselves came out of solution, they were not effective as suspension acids.

Accordingly, the present invention provides a composition which comprises (a) a finely divided solid medicament having a particle size of less than microns, (-b) a propellant and (c) an anionic surface-active agent selected from the group consisting of (i) alkali metal, ammonium and amine salts of dialkyl sulphosuccic acids wherein the alkyl groups contain from 4 to 12 carbon atoms, and (ii) alkali metal, ammonium and amine salts of alkylbenzene sulphonic acids wherein the alkyl groups contain from 8 to 14 carbon acids; said medicament comprising from 0.025 to 20% by weight of the composition and said anionic surface-active agent comprising from about 0.01% to about 10% by weight of the solids content of the composition.

The surface-active agents for present use are preferably selected from the group comprising the salts of dialkyl sulphosuccinic acids wherein the alkyl groups are the same and contain from 4 to 9 carbon atoms, notably the salts of dibutyl-, dioctyland dinonylsulphosuccinic acids; and the salts of alkylbenzene sulphonic acids wherein the alkyl groups contain from 10 to 12 carbon atoms,

notably decyland dodecylbenzene sulphonic acids. The salts for present use may be the alkali metal, ammonium or amine salts of the acids. It will be appreciated that the salts should be selected from amongst those which are therapeutically acceptable. It is preferred to use the sodium salts of the acids.

The medicament is a finely divided solid, having a particle size of less than 100 microns, and preferably is of a particle size of 1-25 microns. Examples of medicaments which may be used include isoprenaline sulphate, atropine methonitrate, adrenaline acid tartrate, ephedrine hydrochloride, ergotamine tartrate, diphenhydramine hydrochloride, hydrocortisone acetate; antibiotics, for example penicillins, streptomycin and tetracycline; and mixtures of any of these together or with other medicaments. The medicament suitably comprises 0.025-20% by weight of the total composition, although larger or smaller proportions may be used if desired. According to a preferred embodiment the total composition contains 0.1-2% by weight of medicament.

The anionic surface-active agent may, as indicated above, be used in very small amounts. The amount of the surface-active agent required is broadly related to the solids content of the suspension and to the particle size of the solids. In general it is only necessary to use 0.0l-2% of the anionic surface-active agent by weight of the solids content of the suspension. It is not necessary to use larger amounts than this and I have found that the use of amounts in excess of from 5% to of the solids content of the suspension provides no advantage. Thus for example, with a suspension of a medicament for inhalation purposes where the composition contains 1% of solids of particle size about 10 microns, satisfactory suspension is obtained using 0.05 to 0.2% of the anionic surface-active agent by weight of the total solids in the composition. However, as indicated above, in some cases it may be possible adequately to suspend widely varying amounts of a powder with a given amount of anionic surface-active agent. The optimum amount of surface-active agent for any given formulation may be readily determined by simple tests of the type exemplified below.

The propellant may be any of the conventional propellants used in aerosol formulations, for example halogenated hydrocarbons of the fluorohydrocarbon or fluorohalohydrocarbon type such as trichloromonofiuoromethane, dichlrodifiuoromethane, dichlorotetrafluoroethane, monochlorotrifiuoromethane, monochlorodifluoromethane and mixtures of any of these together or with other propellants. Typical of suitable propellants are those disclosed in, for example, US. Pat. 2,868,691 and sold under the trademark Freon. As indicated above, it is possible to use certain non-toxic propellants which are incompatible with non-ionic surface-active agents. This is of special benefit when the formulation is to be ingested by the user, eg by inhalation, as opposed to being used externally, e.g. fOr the topical application of an antibiotic dust.

Where the formulations are to be ingested it is preferred to use as liquefied propellants either difluorodichloromethane or dichlorotetrafluoroethane, or mixtures thereof.

It will be appreciated that the various components of the composition of the invention should desirably be substantially anhydrous, that is that the minimum feasible amount of water should be present.

In some cases it may be desirable to add a polar solvent to the formulation; suitable polar solvents for this purpose include ethyl alcohol and isopropyl alcohol.

It may also be desired to add auxiliary solids to the formulation. Thus where the medicament is of density considerably less than that of the propellants, it may be suitable to add a solid inert diluent of high density of the same particle size, so that the density of the combined solids is similar to that of the propellants. Suitable inert solids for this purpose include sodium chloride and sodium sulphate.

The following examples are given to illustrate the present invention in which all percentages are by weight.

EXAMPLE 1 The following composition was prepared and incorporated in a pressurised aerosol package.

Percent Isoprenaline sulphate (particle size 28 microns) 0.1 Atropine methonitrate (particle size 2-8 microns) 0.04 Sodium dioctylsulphosuccinate 0.002 Dichlorotetrafiuoroethane 40 Dichlorodifluoromethane to This composition is useful for the relief of asthmatic conditions and used as in inhalant gives a dry spray which is readily absorbed by the mucous membranes. Furthermore, the solid material remained in suspension for a considerably longer period than when no surface-active agent was present.

EXAMPLE 2 Percent Isoprenaline sulphate (particle size 2-8 microns) 0.1 Atropine methonitrate (particle size 2-8 microns) 0.04 Sodium dibutylsulphosuccinate 0.002 Dichlorotetrafluoroethane 40.00

Dichlorodifluoromethane to 100%.

This composition is useful for the relief of asthmatic conditions and used as an inhalant gives a dry spray which is readily absorbed by the mucous membranes.

The composition was a stable suspension whose settling time was considerably longer than when no surfaceactive agent was present.

EXAMPLE 3 Percent Ephedrine hydrochloride (particle size below 20 microns) 1.0 Sodium chloride (particle size below 20 microns) 1.0 Naphazoline nitrate (particle size below 20 micons) 0.1 Cineole 0.2 Sodium dioctylsulphosuccinate 0.015 Dichlorodifluoromethane 30.0

Dichlorotetrafluoroethane to 100% This formulation is useful as a nasal decongestant. The composition was a stable suspension Whose settling time was considerably longer than when no surface-active agent was present.

Dichlorodifluoromethane to 100%.

EXAMPLE 5 A stable suspension was prepared from the following:

Percent Diphenhydramine hydrochloride (particle size below 25 microns) 0.5 Sodium dinonylsulphosuccinate 0.003 Ethyl alcohol 740.P 2.5 Dichlorodifluoromethane 30.0 Dichlorotetrafluoroethane to 100%.

EXAMPLE 6 A stable suspension was prepared from the following:

Percent Hydrocortisone acetate (particle size below microns) 0.4 Sodium dodecylbenzene sulphonate 0.004 Dichlorotetrafiuoroethane 40.0 Dichlorodifluoromethane to 100%.

6 ume of the aerosol spray and generally affects the ease of use of the composition.

(3) The times taken for the top quarter and the top half of the liquid phase to become substantially clear of suspended solid particles. This is a measure of the stability of the suspension and the tendency of the solid particles to flocculate.

The results of these examinations are set out in Table I below.

TABLE 1 Concentration (percent Settling w./w.) of Ease of time solid resus- Surface-active agent material Appearance pension 25% Sodium dioctylsulphosuccinate 0.05 Slightly flocculant Fair-- 1'19 2'40 0. 075 Very slightly flocculanL. Good 27" 4'9" 0.1 Smooth. 0. 25

1. 0 10.0 do Sorbitan trioleate 0. 05 Flocculant.

0. 1 0. 5 1. 0 do 5110.00 Fairly smoot Control (no surfactant) Flocculant Poor".-. 0'55 1'46 EXAMPLE 7 Examples 1 to 6 demonstrate the formation of stable suspensions using a variety of surface-active agents at concentrations of from 1.8% to 0.6% by weight of the solid medicament present. In all cases the stability of the suspension of the solid material was of the same order, which was considerably greater than when no surfaceactive agent was present.

In order to demonstrate the formation of stable suspensions over a wider range of concentrations, a series of suspensions were prepared using sodium dioctylsulphosuccinate as follows:

Ephedrine hydrochloride (of particle size less than 11 microns, 1%) was suspended in a solution of the surfaceactive agent (varying amounts) in monofluorotrichlord methane (to 100%) and the mixture subjected to high speed stirring in a Guisti stirrer for 5 minutes. By way of comparison, suspensionswere also prepared in the same manner using a typical non-ionic surface-active agent in current use in powder aerosol formulations, Arlacel 85 which is sorbitan trioleate. The suspensions were examined for:

(1) Appearance, since the smoothness of the suspension is an indication of the extent of dispersion of the solid medicament particles.

(2) The ease of re-suspending the suspension after it had been allowed to settle out. This has a profound effect upon the dosage of medicament supplied in a given vol- From the results shown in Table 1 it will be seen that the anionic surface-active agent was an effective suspension aid over a wide range of low concentrations; that it was more effective than the non-ionic material even when used at 5% of the concentration of the nonionic; and that it was not until the concentration of the non-ionic surfaceactive agent was raised to 50.0% that it showed an im provement in effe'ctivity when compared to a concentration of 0.075% of anionic material, i.e. the non-ionic material was present in some 800 times as great an amount.

Furthermore, the results of Table 1 show that the nonionic surface-active agent showed no significant improvement over the control suspension until it was present in a concentration of 10% or more.

I claim:

1. A substantially anhydrous composition consisting essentially of (a) a finely divided solid medicament having a particle size less than microns, (b) a halogenated hydrocarbon propellant having no more than 2 carbon atoms and (c) an anionic surface-active agent se lected from the group consisting of sodium dioctylsulphosuccinate and sodium dodecylbenzene sulphonate; said medicament being present in from 0.025 to 20% by weight of the composition and said anionic surface-active agent being present in from about 0.05% to about 2% by weight of the solids content of the composition.

2. The composition as claimed in claim 1 wherein the anionic surface-active agent is sodium dioctylsulphosuccin-ate.

7 8 3. The composition as claimed in claim 2 wherein the 3,131,152 4/1964 Klausner 167-39A sodium dioctylsulphosuccinate is present in a minimum 2,953,284 9/1960 Prussen et a1 42446 amount of about 0.075% by weight of the solids con ent 3,095,355 6/1963 Abramson 42446 of the composition; 3,169,095 2/1965 Thiel 42446 4. The composition as claimed in claim 1 whereln the 5 3,282,781 11/1966 Macek anionic surface-active agent is sodium dodecylbenzene sulphonate OTHER REFERENCES The composition as claimedfin claim 1 further 9 Di Giacomo: Drug and Cosmetic Industry, September taining an inert high denslty so11d of the same particle 1958; 79 3, me as the medlcament' 10 Schwartz et al.: Surface Active Agents and Detergents,

References Cited vol. II (1958), pp. 312-313.

UNITED STATES PATENTS STANLEY J. FRIEDMAN, Primary Examiner 2,889,243 6/1959 Underwood et a1. 167-82A

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4352789 *Mar 17, 1980Oct 5, 1982Minnesota Mining And Manufacturing CompanyAerosol compositions containing finely divided solid materials
US4405598 *Jan 13, 1981Sep 20, 1983Fisons, LimitedComposition for treating asthma
US5427282 *Jun 17, 1994Jun 27, 1995Minnesota Mining And Manufacturing CompanyUsed for dispensing medicament to respiratory system; inhalation
US6780399May 15, 2002Aug 24, 2004Alexza Molecular Delivery CorporationDelivery of stimulants through an inhalation route
US6884408May 21, 2002Apr 26, 2005Alexza Molecular Delivery CorporationDelivery of diphenhydramine through an inhalation route
US6994843Apr 1, 2004Feb 7, 2006Alexza Pharmaceuticals, Inc.Delivery of stimulants through an inhalation route
US7005121Dec 12, 2003Feb 28, 2006Alexza Pharmaceuticals, Inc.Arerosol; heating drug, vaporization, cooling
US7005122Mar 3, 2004Feb 28, 2006Alexza Pharmaceutical, Inc.Delivery of sumatriptan, frovatriptan or naratriptan through an inhalation route
US7008615Dec 12, 2003Mar 7, 2006Alexza Pharmaceuticals, Inc.Delivery of anti-migraine compounds through an inhalation route
US7008616Apr 1, 2004Mar 7, 2006Alexza Pharmaceuticals, Inc.Ephedrine or fenfluramine; aluminum foil coated with a thin layer of drug is heated to form vapor; which condenses to form aerosol; rapid peak plasma concentration
US7011819Mar 3, 2004Mar 14, 2006Alexza Pharmaceuticals, Inc.Increasing the rate at which the peak plasma concentrations are reached by delivering the drug in a single inspiration from a dispenser in which the condensation aerosol was formed by cooling a vapor formed by heating a thin layer on a support; less than 10% degradation products and a mass median aerosol
US7011820Apr 1, 2004Mar 14, 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of Parkinsons through an inhalation route
US7014840Mar 3, 2004Mar 21, 2006Alexza Pharmaceuticals, Inc.heating a thin coating to form a vapor then allowing to cool to form a condensation aerosol; kits
US7014841Mar 31, 2004Mar 21, 2006Alexza Pharmaceuticals, Inc.Delivery of antiemetics through an inhalation route
US7018619Dec 12, 2003Mar 28, 2006Alexza Pharmaceuticals, Inc.Administering a therapeutic amount of an alprazolam, estazolam, midazolam or triazolam condensation aerosol for therapy of anxiety or insomnia
US7018620Feb 9, 2004Mar 28, 2006Alexza Pharmaceuticals, Inc.Delivery of beta-blockers through an inhalation route
US7018621Mar 3, 2004Mar 28, 2006Alexza Pharmaceuticals, Inc.dosage form serotonin agonists comprising aerosols formed by heating layers of the drugs on solid supports, to form vapors, then condensing to form condensates which can be administered by breathing; prophylaxis of headaches
US7022312Mar 31, 2004Apr 4, 2006Alexza Pharmaceuticals, Inc.Condensation aerosol as doage forms, is produced by heating a thin layer containing of dolasetron, granisetron or metoclopramide to form vapor, condense into an aerosol; fast producing peak plasma concentrations
US7029658Dec 12, 2003Apr 18, 2006Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US7033575Jan 30, 2004Apr 25, 2006Alexza Pharmaceuticals, Inc.Delivery of physiologically active compounds through an inhalation route
US7045118Jan 27, 2004May 16, 2006Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of migraine through an inhalation route
US7045119Mar 3, 2004May 16, 2006Alexza Pharmaceuticals, Inc.Delivery of diazepam through an inhalation route
US7048909Feb 9, 2004May 23, 2006Alexza Pharmaceuticals, Inc.Aerosols containing nondegraded atenolol, pindolol, esmolol, propranolol, or metoprolol
US7052679Jan 28, 2004May 30, 2006Alexza Pharmaceuticals, Inc.thin film of drugs; heating; dispensing as aerosol condensation
US7052680Apr 1, 2004May 30, 2006Alexza Pharmaceuticals, Inc.aerosols containing antiparkinsons drugs benzotropine, pergolide, amantadine, deprenyl and ropinerole, that have been heated on a solid support such as foil and condensed by passing through a flow of air
US7060254Jan 27, 2004Jun 13, 2006Alexza Pharmaceuticals, Inc.Aerosol; heating thin film on solid support; vaporization with air flow
US7060255Jan 29, 2004Jun 13, 2006Alexza Pharmaceuticals, Inc.Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
US7063830Jan 29, 2004Jun 20, 2006Alexza Pharmaceuticals, Inc.condensation aerosol for delivery of lidocaine, verapamil, diltiazem, isometheptene and lisuride, wherein aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form aerosol
US7063831Jan 29, 2004Jun 20, 2006Alexza Pharmaceuticals, Inc.Delivery of erectile dysfunction drugs through an inhalation route
US7063832Mar 31, 2004Jun 20, 2006Alexza Pharmaceuticals, Inc.Treating musculoskeletal pain or restless leg syndrome by breathing a muscle relaxant condensation aerosol having a mass median aerodynamic diameter (MMAD) of <3 mu m and <5% relaxant degradation products; kits; heating a coating of drug on a support to vaporize and passing air through the heated vapors
US7067114Jan 29, 2004Jun 27, 2006Alexza Pharmaceuticals, Inc.Delivery of antihistamines through an inhalation route
US7070761Dec 12, 2003Jul 4, 2006Alexza Pharmaceuticals, Inc.Aerosols; heating, vaporization, cooling
US7070762Dec 12, 2003Jul 4, 2006Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US7070763Jan 27, 2004Jul 4, 2006Alexza Pharmaceuticals, Inc.Delivery of diphenhydramine through an inhalation route
US7070764Jan 27, 2004Jul 4, 2006Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US7070765Jan 29, 2004Jul 4, 2006Alexza Pharmaceuticals, Inc.condensation aerosol formed by heating a thin layer containing the ester, on a solid support to produce a vapor of the ester, and condensing the vapor; less than 10% ester degradation products by weight, and a Mass median aerodynamic diameter of less than 5 microns.
US7070766Jan 30, 2004Jul 4, 2006Alexza Pharmaceuticals, Inc.Delivery of physiologically active compounds through an inhalation route
US7078016Nov 21, 2002Jul 18, 2006Alexza Pharmaceuticals, Inc.Delivery of caffeine through an inhalation route
US7078017Dec 30, 2003Jul 18, 2006Alexza Pharmaceuticals, Inc.Delivery of sedative-hypnotics through an inhalation route
US7078018Dec 30, 2003Jul 18, 2006Alexza Pharmaceuticals, Inc.Aerosol therapy; heating, vaporization, cooling, condensation; analgesics; alcoholism
US7078019Dec 30, 2003Jul 18, 2006Alexza Pharmaceuticals, Inc.Heating a drug ester to vaporize; cooling to form condensation aerosol; drug delivery kit for dispensing thin coatings
US7078020Dec 30, 2003Jul 18, 2006Alexza Pharmaceuticals, Inc.Heating antipsychotic drug to vaporize; cooling to form condensation aerosol; kit for dispensing thin coating
US7087216Jan 27, 2004Aug 8, 2006Rabinowitz Joshua DCondensation aerosol for delivery of a drug selected from the group consisting of zaleplon, zolpidem and zopiclone
US7087217Jan 27, 2004Aug 8, 2006Alexza Pharmaceuticals, Inc.Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone
US7087218Mar 3, 2004Aug 8, 2006Alexza Pharmaceuticals, Inc.Delivery of diazepam through an inhalation route
US7090830Nov 20, 2003Aug 15, 2006Alexza Pharmaceuticals, Inc.formed by heating thin film of drug composition to produce vapor, condensing the vapor to form aerosol comprising heat stable drug
US7094392Dec 30, 2003Aug 22, 2006Alexza Pharmaceuticals, Inc.Heating antihistamine drug vaporize; cooling to form a condensation aerosol; kit for dispensing thin coating
US7108847Mar 31, 2004Sep 19, 2006Alexza Pharmaceuticals, Inc.Delivery of muscle relaxants through an inhalation route
US7115250Dec 30, 2003Oct 3, 2006Alexza Pharmaceuticals, Inc.Heating erectile dysfunction drug to vaporize; cooling to form condensation aerosol; drug delivery
US7169378Jan 29, 2004Jan 30, 2007Alexza Pharmaceuticals, Inc.Delivery of opioids through an inhalation route
US7442368Mar 7, 2006Oct 28, 2008Alexza Pharmaceuticals, Inc.Rapidly producing peak plasma concentration; condensation aerosol containing ephedrine and/or fenfluramine; vaporization without degradation
US7445768Aug 7, 2006Nov 4, 2008Alexza Pharmaceuticals, Inc.Delivery of sedative-hypnotics through an inhalation route
US7449172Apr 4, 2006Nov 11, 2008Alexza Pharmaceuticals, Inc.Delivery of antiemetics through an inhalation route
US7449173Jun 13, 2006Nov 11, 2008Alexza Pharmaceuticals, Inc.heating drugs used for the treatment of anxiety or insomnia, coated on solid supports to form vapors and condensing the vapor to form aerosols comprising microstructure particles of the drugs
US7449174Jun 30, 2006Nov 11, 2008Alexza Pharmaceuticals, Inc.Delivery of analgesics through an inhalation route
US7449175Jul 5, 2006Nov 11, 2008Alexza Pharmaceuticals, Inc.Delivery of erectile dysfunction drugs through an inhalation route
US7458374May 13, 2002Dec 2, 2008Alexza Pharmaceuticals, Inc.Method and apparatus for vaporizing a compound
US7465435May 24, 2006Dec 16, 2008Alexza Pharmaceuticals, Inc.Delivery of beta-blockers through an inhalation route
US7465436May 30, 2006Dec 16, 2008Alexza Pharmaceuticals, Inc.Aerosol for delivery of benzotropine, pergolide, amantadine, deprenyl, or ropinerole, formed by vaporizing the drug that is coated on a solid support and condensing the vapor to form particles containing least 10 % by weight of the drug and less than 5 % by weight of degradation products
US7465437Jun 16, 2006Dec 16, 2008Alexza Pharmaceuticals, Inc.Delivery of anti-migraine compounds through an inhalation route
US7468179Jan 9, 2007Dec 23, 2008Alexza Pharmaceuticals, Inc.Aerosol for delivery of naltrexone, buprenorphine, nalbuphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanil, sufentanil, or fentanyl by vaporizing the drug, which is coated on support and condensing to form aerosol with mass median aerodynamic diameter of less than 5 microns
US7470421Aug 7, 2006Dec 30, 2008Alexza Pharmaceuticals, IncDelivery of diazepam through an inhalation route
US7485285Jun 13, 2006Feb 3, 2009Alexza Pharmaceuticals, Inc.Delivery of antidepressants through an inhalation route
US7488469Jul 18, 2006Feb 10, 2009Alexza Pharmaceuticals, Inc.Delivery of caffeine through an inhalation route
US7491047Aug 22, 2006Feb 17, 2009Alexza Pharmaceuticals, Inc.Delivery of antihistamines through an inhalation route
US7498019Mar 21, 2006Mar 3, 2009Alexza Pharmaceuticals, Inc.Delivery of compounds for the treatment of headache through an inhalation route
US7507397Sep 19, 2006Mar 24, 2009Alexza Pharmaceuticals, Inc.Delivery of muscle relaxants through an inhalation route
US7507398Jun 30, 2006Mar 24, 2009Alexza Pharmaceuticals, Inc.Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention
US7510702Aug 7, 2006Mar 31, 2009Alexza Pharmaceuticals, Inc.Condensation aerosol for delivery of a drug selected from the group consisting of indomethacin, ketoprofen, celcoxib, rofecoxib, meclofenamic acid, fenoprofen, diflunisal, tolfenamic acid, naproxen, ibuprofen, flurbiprofen and nabumetone
US7524484Jun 30, 2006Apr 28, 2009Alexza Pharmaceuticals, Inc.Delivery of diphenhydramine through an inhalation route
US7537009May 13, 2002May 26, 2009Alexza Pharmaceuticals, Inc.heating a substrate coated with formulation containing a drug ( e.g. antibiotics, antidepressants, antihistamines etc.) for a period of time, to form a vapor in less than 500 milliseconds, allowing the vapor to cool; absence of excipients
US7540286Jun 3, 2004Jun 2, 2009Alexza Pharmaceuticals, Inc.Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US7550133Nov 20, 2003Jun 23, 2009Alexza Pharmaceuticals, Inc.comprise respiratory drug condensation aerosol particles; selected from the group consisting of beta -adrenergics, methylxanthines, anticholinergics, corticosteroids, mediator-release inhibitors, anti-leukotriene drugs, asthma inhibitors etc
US7581540Aug 12, 2004Sep 1, 2009Alexza Pharmaceuticals, Inc.Aerosol drug delivery device incorporating percussively activated heat packages
US7585493Aug 4, 2003Sep 8, 2009Alexza Pharmaceuticals, Inc.Thin-film drug delivery article and method of use
US7601337Jul 18, 2006Oct 13, 2009Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US7645442Aug 4, 2003Jan 12, 2010Alexza Pharmaceuticals, Inc.Device including heat source is operable to supply heat to substrate to produce substrate temperature greater than 300 degrees C., and to substantially volatilize drug composition film from substrate in 2 seconds or less
US7766013Oct 26, 2001Aug 3, 2010Alexza Pharmaceuticals, Inc.Aerosol generating method and device
US7913688May 20, 2003Mar 29, 2011Alexza Pharmaceuticals, Inc.Inhalation device for producing a drug aerosol
US7942147May 13, 2002May 17, 2011Alexza Pharmaceuticals, Inc.Aerosol forming device for use in inhalation therapy
US7981401Feb 2, 2007Jul 19, 2011Alexza Pharmaceuticals, Inc.Diuretic aerosols and methods of making and using them
US7987846Nov 21, 2008Aug 2, 2011Alexza Pharmaceuticals, Inc.Method and apparatus for vaporizing a compound
US7988952Mar 27, 2008Aug 2, 2011Alexza Pharmaceuticals, Inc.Condensation aerosol formed by heating a thin layer containing the ester, on a solid support to produce a vapor of the ester, and condensing; less than 10% ester degradation products by weight, and a Mass median aerodynamic diameter of less than 5 microns
US8003080May 13, 2003Aug 23, 2011Alexza Pharmaceuticals, Inc.Delivery of drug amines through an inhalation route
US8074644May 22, 2009Dec 13, 2011Alexza Pharmaceuticals, Inc.Method of forming an aerosol for inhalation delivery
US8173107Mar 27, 2009May 8, 2012Alexza Pharmaceuticals, Inc.Delivery of antipsychotics through an inhalation route
US8235037May 8, 2008Aug 7, 2012Alexza Pharmaceuticals, Inc.Impermeable heat-conductive substrate coated with alprazolam, fentanyl, loxapine, prochlorperazine or zaleplon and a heat source that can supply heat to the substrate at a rate that can vaporize all or a portion of the coated drug within a period of 2 seconds
US8288372Nov 20, 2003Oct 16, 2012Alexza Pharmaceuticals, Inc.Method for treating headache with loxapine
US8333197May 29, 2009Dec 18, 2012Alexza Pharmaceuticals, Inc.Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US8387612Jun 16, 2009Mar 5, 2013Alexza Pharmaceuticals, Inc.Self-contained heating unit and drug-supply unit employing same
US8506935Jun 23, 2009Aug 13, 2013Alexza Pharmaceuticals, Inc.Respiratory drug condensation aerosols and methods of making and using them
DE2703119A1 *Jan 26, 1977Aug 4, 1977Fisons LtdDinatriumcromoglycat mit weniger als 5 % wasser und dieses umfassende pharmazeutische praeparate
EP0275404A1 *Nov 23, 1987Jul 27, 1988Abbott LaboratoriesLHRH analog formulations
EP0510731A1 *Nov 23, 1987Oct 28, 1992Abbott LaboratoriesLHRH Analog formulations
WO2002094216A2 *May 15, 2002Nov 28, 2002Alexza Molecular Delivery CorpDelivery of stimulants through an inhalation route
WO2002094239A1 *May 21, 2002Nov 28, 2002Alexza Molecular Delivery CorpDelivery of diphenhydramine through an inhalation route
Classifications
U.S. Classification424/46
International ClassificationB05B9/04, A61K31/57, A61K31/16, G01N27/84, A61K31/48, A61K31/14, B65D83/14, A61K31/46, A61K9/00
Cooperative ClassificationA61K31/46, A61K31/48, B65D83/752, A61K9/008, A61K31/57, A61K31/14
European ClassificationA61K31/46, B65D83/752, A61K31/48, A61K9/00M20B6, A61K31/14, A61K31/57